Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:IRWD 2 January 2026 - 5 January 2026

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals shares rose about 1% premarket Monday after Citizens upgraded the stock, citing eased pricing pressure on Linzess. The company last week cut Linzess’s list price by about 50% and forecast 2026 revenue of $450–$475 million. Shares closed up 26.7% Friday at $4.27, with trading volume surging to 85 million. Ironwood remains in a strategic alternatives review and plans a Phase 3 apraglutide trial in 2026.
5 January 2026
··
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Ironwood Pharmaceuticals shares jumped 26.7% Friday to $4.27 after the company issued 2026 guidance, forecasting total revenue of $450 million to $475 million and adjusted EBITDA above $300 million. The company expects 2026 Linzess U.S. net sales of $1.125 billion to $1.175 billion after lowering the drug’s list price on Jan. 1. Investors await a fourth-quarter update on the apraglutide Phase 3 trial and strategic review.
4 January 2026
·
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie shares rose 0.2% to $228.95 after Ironwood Pharmaceuticals, its Linzess partner, raised 2026 U.S. net sales guidance and cut the drug’s list price effective Jan. 1. Ironwood shares jumped 29.5%. Ironwood now expects 2026 Linzess U.S. net sales of $1.125–$1.175 billion, up from 2025’s $860–$890 million forecast. Wall Street trading was muted as investors awaited U.S. labor data and watched for broader drug pricing moves.
2 January 2026
···

Stock Market Today

  • Evertz Technologies Fair Value Targets Lifted by Analysts on TSX
    March 20, 2026, 2:37 PM EDT. Analysts have raised the fair value estimate for Evertz Technologies (TSX:ET) from CA$14.88 to CA$17.25, reflecting a roughly 16% increase and aligning with a cluster of price targets between CA$16 and CA$17.50. Canaccord and BMO Capital have each lifted their price targets to CA$17.50, maintaining positive ratings, while RBC Capital has raised its target incrementally to CA$16 but retains a cautious Sector Perform stance. The upward revisions follow updated assumptions, including a slight dip in revenue growth to 4.16% and an improved net profit margin to 12.98%. The stock's quarterly dividend was declared at CA$0.2050 per share, payable March 2026. Investors should note the narrowed upside range and potential risks flagged, advising careful consideration of entry points and expectations.
Go toTop